Ozempic and Mounjaro Prior Authorization for Type 2 Diabetes: Criteria and Denials

If your pharmacy says Ozempic or Mounjaro "needs a prior authorization," it can feel like the plan doubts your diagnosis. Usually it is not personal. The plan is checking that the drug is going to someone with type 2 diabetes, which is what these products are approved for, and not to someone using it only to lose weight.

This guide explains why that check exists, what plans commonly ask for, why requests get denied, and what documentation tends to get them approved. It is general information, not medical advice. Your prescriber and your plan's own criteria document decide what applies to you.

Why Ozempic and Mounjaro need prior authorization

Both drugs are FDA-approved for type 2 diabetes. The current Ozempic label (revised May 2026) lists three uses in adults with type 2 diabetes:

• improving blood sugar control;
• reducing the risk of major cardiovascular events in people with established cardiovascular disease;
• reducing the risk of kidney decline, end-stage kidney disease and cardiovascular death in people with chronic kidney disease.

The Mounjaro label (revised August 2026) covers blood sugar control in adults and children 10 and older with type 2 diabetes. It also covers reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk of them.

Neither label includes weight loss, but both drugs cause it, and the same molecules are sold under weight-loss labels (see below). Many plans exclude weight-loss drugs, so prior authorization stops a diabetes GLP-1 from becoming a back door around that exclusion.

Insurer policies say this directly:

• UnitedHealthcare's GLP-1 diabetes policy (effective July 1, 2026) says Mounjaro and Ozempic "are not FDA approved for the treatment of weight loss" and that weight-loss medications "are typically excluded from benefit coverage." Its change log shows the criteria were updated in 2022 so that use "is not solely for weight loss."
• Cigna's national formulary policy (reviewed June 2026) lists "Weight Loss Treatment" as not medically necessary for these drugs, with a note that patients who do have type 2 diabetes are handled under the diabetes criteria.

Cost is the other driver. CMS lists the 2024 list price of Ozempic at $959 for a 30-day supply.

Same molecules, different labels: Ozempic and Mounjaro vs Wegovy and Zepbound

There are two semaglutide injections and two tirzepatide injections, each approved for different purposes and covered under different rules.

In practice:

• If you have type 2 diabetes, the diabetes-labeled product (Ozempic or Mounjaro) is normally the one your plan evaluates, under its diabetes criteria.
• If you do not have type 2 diabetes, a request for Ozempic or Mounjaro is likely to be denied. The request would need to go through the plan's obesity-drug rules for Wegovy or Zepbound, if the plan covers them at all.
• Plans generally will not approve two of these drugs together. Cigna's policy excludes combining them with each other or with any other GLP-1 or GIP/GLP-1 drug.

For the drug-level differences, see Ozempic vs Wegovy: the same drug and Mounjaro vs Zepbound. To compare the two diabetes drugs, see Ozempic vs Mounjaro.

What plans commonly ask for

No single national rule exists. Below are the criteria that come up most often, with real plan examples to show how much they vary. Your plan or your prescriber's office can get you your plan's exact criteria.

1. A type 2 diabetes diagnosis you can prove

This is the one near-universal requirement. How plans check it differs:

• Chart notes with a lab value. UnitedHealthcare requires medical records confirming type 2 diabetes with one of these: A1C of 6.5% or higher; fasting plasma glucose of 126 mg/dL or higher; 2-hour glucose of 200 mg/dL or higher during an oral glucose tolerance test; or a random glucose of 200 mg/dL or higher with classic symptoms of high blood sugar.
• Chart notes alone for long-standing diabetes. The same UnitedHealthcare policy accepts medical records confirming the diagnosis, without the lab-value requirement, for patients diagnosed more than two years ago.
• Diagnosis codes. Type 2 diabetes codes in the ICD-10-CM system start with E11 (for example, E11.9 is "type 2 diabetes mellitus without complications" and E11.65 is "type 2 diabetes mellitus with hyperglycemia"). A prescription coded only for obesity (E66.x) or prediabetes (R73.03) does not show type 2 diabetes. Cigna's policy lists prediabetes and metabolic syndrome without type 2 diabetes as not covered.

2. A metformin trial (sometimes more)

Step therapy is common, but the size of the step varies more than most articles admit:

• No step at all. UnitedHealthcare's commercial policy has no metformin requirement. Its change log shows step-therapy language was removed in April 2024.
• Metformin first. Many plans require a documented trial of metformin, or a documented intolerance or contraindication, before a GLP-1. A September 2026 review of GLP-1 prior authorization in Family Practice Management (AAFP) describes a 90-day "fail-first" metformin trial as a typical requirement, with exceptions for contraindications such as advanced kidney disease.
• Several steps. A Kaiser Permanente Mid-Atlantic form for Maryland Medicaid (effective August 4, 2026) sets out several steps. Before any non-preferred GLP-1, including Ozempic and Mounjaro, it requires failure of an adequate trial of metformin, an SGLT2 inhibitor, and liraglutide. "Adequate" means at least 3 months with at least 80% adherence, unless the drug caused intolerance or is contraindicated. For Mounjaro, it also asks about a trial of, intolerance to, or contraindication to Ozempic.

If you want the background on why metformin is so often the first step, see GLP-1s and metformin.

Guidelines have moved faster than some step rules. The American Diabetes Association's 2026 Standards of Care recommend a medication with proven cardiovascular benefit, such as a GLP-1 receptor agonist or SGLT2 inhibitor, for adults with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease, "irrespective of A1C," and describe metformin as "historically" the first-line treatment. Your prescriber can cite this in a medical-necessity argument; whether the plan accepts it is up to the plan.

3. Other checks plans commonly run

• Age. Cigna approves Ozempic injection for patients 18 and older and Mounjaro for patients 10 and older, matching the labels.
• No overlapping drugs. Plans commonly check that you are not also on another GLP-1 or GIP/GLP-1 drug. Some, like the Kaiser Maryland Medicaid form, also ask about DPP-4 inhibitors (for example sitagliptin).
• Preferred-drug order. Some formularies prefer one GLP-1 over another and want a trial of the preferred one first. For help choosing between them clinically, see best GLP-1 for type 2 diabetes.

Sometimes the approval is automatic

Some plans approve the claim at the pharmacy counter when your claims history already shows diabetes treatment.

• UnitedHealthcare says it may approve initial and renewal requests "based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic."
• Cigna's policy describes automation for Mounjaro. The claim goes through if you have a claim for at least one oral diabetes medicine in the past 130 days and meet the age limit. Single-ingredient metformin and Rybelsus do not count toward that lookback.

So a patient on metformin alone may still face a manual PA with Cigna. Plans change these rules often.

Common denial reasons

The denial letter should give the reason. These are the ones that come up most, drawn from the plan criteria above and the AAFP review:

1. No proof of type 2 diabetes in the records sent. A prescription alone is not enough under policies like UnitedHealthcare's, which ask for chart notes.
2. Only a recent, well-controlled A1C was attached. The AAFP review flags this one. If your diabetes is already controlled on other drugs, your latest A1C may be below 6.5% and can trigger an automatic denial. The fix is to include the historical labs that established the diagnosis.
3. The step-therapy record is missing. You took metformin, but the chart does not show the dose, the dates, or why it was stopped.
4. The diagnosis code points to weight, not diabetes. An obesity or prediabetes code on the request reads as weight-loss use.
5. Overlapping therapy. Another GLP-1, a GIP/GLP-1, or (on some plans) a DPP-4 inhibitor is still on your medication list.
6. Non-preferred drug. The plan wants a trial of its preferred GLP-1 first.
7. Not the right diagnosis for the drug. Cigna lists type 1 diabetes as not covered for these drugs.

Documentation that helps

Ask your prescriber's office whether the submission includes:

• The type 2 diabetes diagnosis code (E11.x) on the request.
• Diagnostic labs. Include the A1C or glucose result that established the diagnosis, not just the most recent one, plus the current A1C.
• Diabetes medication history. For each drug: name, dose, start and stop dates, and the result (not enough effect, side effects, or why it is not appropriate for you).
• Relevant conditions. Established cardiovascular disease or chronic kidney disease, which match specific label uses and ADA recommendations.
• A current medication list that shows no overlapping GLP-1 or DPP-4 drug, or a note that it will be stopped.
• A short medical-necessity note if you are asking the plan to skip a step, explaining the clinical reason.

You can help by gathering pharmacy records of past diabetes prescriptions, especially from a previous doctor or plan. The step therapy guide covers documenting a "failed" trial; it is written for Wegovy and Zepbound, but the principles are the same.

Timelines and renewals

How long the decision takes. It depends on the type of coverage:

• Medicare Part D: plans must decide a standard coverage determination within 72 hours and an expedited one within 24 hours. For exception requests, the clock does not start until the plan receives your prescriber's supporting statement.
• Marketplace and other plans that must cover essential health benefits: federal rules give the same 72-hour (standard) and 24-hour (expedited, for urgent circumstances) limits for drug exception requests, meaning asking for a drug the plan does not normally cover.
• Other commercial plans: standard PA turnaround varies by plan and state. Ask the plan for its turnaround time when your prescriber submits.

How long the approval lasts. Examples from the policies we reviewed:

• UnitedHealthcare and Cigna approve for 12 months.
• The Kaiser Permanente Maryland Medicaid form approves for 6 months at a time.

What renewal asks for. Some renewals simply re-confirm the diagnosis. Others want proof the drug is working. On the Kaiser Maryland Medicaid form, renewal for a non-preferred GLP-1 (for patients without cardiovascular disease or high cardiovascular risk) requires one of three things:

• reaching your A1C goal;
• a 1-point A1C drop from before you started the GLP-1;
• a 0.5-point drop since the last review.

That is one reason to keep your pre-treatment A1C on file.

If you switch plans or employers, expect to go through PA again. The Kaiser form states that new members started on therapy elsewhere must meet the full initial criteria.

Medicare Part D and the diabetes indication

Medicare Part D covers GLP-1s prescribed for type 2 diabetes through your regular Part D or Medicare Advantage drug plan. Each plan sets its own formulary and PA rules. CMS guidance on the new Medicare GLP-1 Bridge says patients using these drugs for type 2 diabetes "should continue to obtain their GLP-1 through their Part D plan." CMS also says it will monitor plans so they do not shift coverage from Part D to the Bridge. The Bridge itself (July 1, 2026 through December 31, 2027) is for weight management with Wegovy and Zepbound. Our Medicare GLP-1 coverage guide covers it in full.

What matters for a Medicare patient with diabetes:

• Out-of-pocket cap. In 2026, your out-of-pocket spending on covered Part D drugs is capped at $2,100 for the year. After that you pay nothing more for covered drugs that year.
• No manufacturer savings cards. The Ozempic and Mounjaro savings programs exclude Medicare, including Part D and Medicare Advantage.
• Negotiated price from 2027. Ozempic, Rybelsus and Wegovy were selected together for Medicare drug price negotiation. The negotiated price of $274 for a 30-day supply takes effect January 1, 2027. CMS lists the 2024 list price as $959. What you personally pay still depends on your plan's cost sharing.
• If the plan says no. You, your representative or your prescriber can ask for a redetermination (the first appeal level) within 65 days of the denial notice. The plan must decide within 7 days (standard) or 72 hours (expedited).

Savings cards for commercially insured patients

Once your PA is approved on a commercial plan, the manufacturer savings card can bring your copay down sharply. The current terms, as published by the manufacturers:

Ozempic (Novo Nordisk)

• Commercially insured patients with Ozempic coverage can pay as little as $25 a month.
• Savings are capped at $100 a month, for up to 48 months.
• Government beneficiaries are excluded.
• For people paying out of pocket, NovoCare Pharmacy lists $349 a month for 0.25 mg, 0.5 mg or 1 mg, and $499 a month for 2 mg. New patients get an introductory $199 a month for two fills of the starting doses through December 31, 2026.

Mounjaro (Lilly)

• With commercial insurance that covers Mounjaro, you can pay as little as $25 for a 1-, 2- or 3-month fill.
• Savings are capped at $150 a month and $1,950 a calendar year.
• Lilly also lists a price "as low as $499" for a 1-month fill for commercially insured patients whose plan does not cover Mounjaro.
• The card requires a prescription for an FDA-approved use, excludes Medicare, Medicaid and other government programs, and expires December 31, 2026.

In short, the $25 price generally depends on the PA being approved first. Enrollment steps, fine print and pitfalls are in our GLP-1 savings card guide.

If your prior authorization is denied

A denial is often fixable when the problem is paperwork rather than eligibility.

1. Read the stated reason. It tells you which gap to close.
2. Ask whether a corrected resubmission is faster than an appeal, for example if the fix is attaching the diagnostic A1C or metformin history.
3. Ask your prescriber about a peer-to-peer call if the dispute is clinical, such as skipping a step because of kidney or heart disease.
4. File a formal appeal if needed, within the deadline (65 days for Medicare Part D; commercial plans state theirs in the denial letter).

Our step-by-step GLP-1 prior authorization appeal guide walks through internal appeals, peer-to-peer review and external review. The insurance coverage overview explains how to find your plan's formulary and criteria documents.

The short version

For a patient with documented type 2 diabetes, an Ozempic or Mounjaro PA is mostly a documentation exercise. Get the diagnosis code, the diagnostic labs and the full medication history into the first submission, check your plan's step rules, and note the renewal date.

Related coverage guides

• GLP-1 letter of medical necessity (with template)
• Zepbound prior authorization
• Wegovy prior authorization
• If your employer dropped GLP-1 coverage
• GLP-1 coverage by PBM (CVS Caremark, Express Scripts, Optum Rx)
• How to appeal a GLP-1 prior authorization denial
• Step therapy for Wegovy and Zepbound